This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through June 1, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical-devices: Archive
OraSure Files for FDA Review of Molecular Self-Test & Colli-Pee Device
by Zacks Equity Research
OSUR files FDA applications seeking approval for two at-home STI tests, advancing decentralized diagnostics; shares gain 3.8% as it targets long-term growth.
medical medical-devices
Hologic's Breast Health Unit Stays In Focus in 2026: What Lies Ahead?
by Moumi Mondal
HOLX's Breast Health unit is back in focus as a proposed Blackstone-TPG deal adds a $76 cash offer and CVR to 2026-27 revenue goals.
medical medical-devices
Should Labcorp Stock Stay in Your Portfolio Right Now?
by Zacks Equity Research
LH's growth bets in specialty testing and acquisitions support its outlook, but macro pressures and currency headwinds remain key risks.
medical medical-devices
OPKO Health Bets on RAYALDEE and Pipeline Progress for 2026 Growth
by Zacks Equity Research
OPK leans on RAYALDEE momentum and strategic partnerships as pipeline trials advance, though reliance on its lone U.S. drug adds risk.
medical medical-devices
McKesson Builds Earnings Momentum on Specialty and Automation
by Zacks Equity Research
McKesson posts a strong fiscal second quarter, lifts full-year EPS outlook, and shows how specialty growth and automation are reshaping its earnings power.
medical medical-devices
Here's Why You Should Retain Masimo Stock in Your Portfolio Now
by Zacks Equity Research
MASI's strong Q3 2025 results, FDA clearance and partnerships fuel growth hopes, but SET dependence and reimbursement risks linger.
medical medical-devices
Hims & Hers Expands Data-Driven, AI-Enabled Care and Personalization
by Debanjana Dey
HIMS deepens its AI and data strategy with personalized care tools, biomarker tracking, and smarter treatment matching.
medical medical-devices
Watch 5 AI-Powered Medical Stocks for a Strong Portfolio in 2026
by Nalak Das
LLY, MDT, ISRG, REGN and JNJ are five defensive medical stocks using AI to drive growth, diagnostics and innovation into 2026.
medical medical-devices pharmaceuticals
Hologic Trading Near 52-Week High: How Should You Play the Stock?
by Moumi Mondal
HOLX nears its 52-week high on diagnostics growth and AI adoption, while tariffs and challenges in China continue to pose risks.
medical medical-devices
CapsoVision Submits FDA 510(k) for AI-Assisted Module in CapsoCam Plus
by Zacks Equity Research
CV seeks FDA clearance to add AI-based reading to CapsoCam Plus to boost diagnostic accuracy and streamline reviews.
medical medical-devices